Digital & Computational Pathology - Director of Biomarker Discovery, Small Pharma

A director of biomarker discovery at a small pharma company discusses how they utilize and implement digital pathology, with a focus on how the technology is used specifically within their organization. They mention that they use digital pathology across research applications, incorporating it into both translational to clinical research, for assay development and sample analysis. The stakeholder also mentions being familiar with several digital pathology vendors, including Hamamatsu, Roche, Leica, PathAI, Tempus, and Flagship Biosciences. They express frustration with the difficulty of image analysis, a lack of validated data, as well as the high cost associated with implementing digital workflows. This stakeholder also discusses the potential digital pathology technology has to replace actual pathology assessments for some of the validated tests, with companies like PathAI showcasing the value of using digital platforms and identifying patterns in H&E stains that correlate with response to treatment.

‍